PROK

ProKidney Corp. (NASDAQ:PROK) is a clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. The company went public in June 2021 and focuses on developing innovative cellular therapy treatments for kidney diseases. ProKidney is currently advancing its lead product candidate, Renal Autologous Cell Therapy (REACT), through Phase III clinical trials for diabetic kidney disease, representing a potentially groundbreaking approach to treating chronic kidney conditions that affect millions of patients worldwide.